Ask AI
ProCE Banner Events

Share

Managing Agitation Associated With Alzheimer’s Disease: Best Practices for Now and Planning for the Future

Join us for a presentation on agitation associated with Alzheimer’s disease (AAD) at the 2023 Contemporary Pharmacology Conference, being hosted by GAPNA in Honolulu, Hawaii. The presentation will provide expert guidance on managing patients with AAD, including best practices for using currently available pharmacologic options and a discussion of patient factors that impact a risk-benefit decision when choosing a therapeutic agent. This talk will also cover emerging pharmacologic options and insights on how they might impact future clinical practice.

Unable to join us in Honolulu? An on-demand webcast will soon be available for viewing.

Meeting space has been assigned to provide an educational session supported by Clinical Care Options, LLC during GAPNA’s 2023 Pharmacology Conference, April 25 – April 29 in Honolulu, Hawaii. GAPNA’s assignment of meeting space does not imply product endorsement nor does GAPNA assume any responsibility for the educational content of the educational session.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Psychologists: 1.00 APA CE Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Social Workers: 1.00 ASWB ACE CE Credit

This event has expired. No longer available for credits.

Credits Available

1.0

Who Should Attend

This program is intended for healthcare professionals caring for patients with AAD including physicians (psychiatrists and geriatricians), nurse practitioners, physician associates/physician assistants, nurses, pharmacists, psychologists, and social workers.

Time and location

Saturday, April 29, 2023

6:55 AM - 7:55 AM Hawaii-Aleutian Standard Time (HAST)

In-person

Hilton Hawaiian Village
2005 Kalia Road
Honolulu, Hawaii 96815

Honolulu Salon 1 - 3

Faculty
George T. Grossberg, MD

Henry & Amelia Nasrallah Professor
Director, Geriatric Psychiatry
Department of Psychiatry & Behavioral Neuroscience
St Louis University School of Medicine
St Louis, Missouri

Agenda

Registration and Breakfast: 6:30 AM – 6:55 AM

Satellite: 6:55 AM – 7:55 AM

  • Welcome and Introduction
  • Overview of Agitation in Alzheimer’s Disease
    • Prevalence and pathophysiology
    • Diagnostic criteria
  • Current Treatment Options for AAD
    • Nonpharmacologic approach
    • Pharmacologic approach
      • Differing mechanisms of action and receptor binding profiles
      • Efficacy and safety profiles, including risk-benefit analysis
  • Emerging Treatment Options for AAD
    • Pharmacologic rationale for novel agents
      • Differing mechanisms of action and receptor binding profiles 
      • Efficacy and safety data 
  • Conclusions and Audience Q&A

Location

Venue Name

Hilton Hawaiian Village

Address

Hilton Hawaiian Village
2005 Kalia Road
Honolulu, Hawaii 96815

Room Name

Honolulu Salon 1 - 3

CME/CE Info

Program Overview
This presentation will provide expert guidance on managing patients with AAD, including best practices for using currently available pharmacologic options and a discussion of patient factors that impact a risk-benefit decision when choosing a therapeutic agent. This talk will also cover emerging pharmacologic options and insights on how they might impact future clinical practice.

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to optimize treatment for patients with AAD.

Target Audience
This program is intended for healthcare professionals caring for patients with AAD including physicians (psychiatrists and geriatricians), nurse practitioners, physician associates/physician assistants, nurses, pharmacists, psychologists, and social workers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Create an individualized treatment plan for a patient with AAD, considering the safety of current treatment options
  • Recognize the mechanisms of action of emerging treatment options for AAD
  • Assess clinical evidence for emerging options for the treatment of AAD

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacology credit.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-081-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Psychologist Continuing Education

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity will offer 1.0 continuing education credit for psychologists.

Social Work Continuing Education

As a Jointly Accredited Organization, Clinical Care Options, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 clinical continuing education credit.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners to optimize treatment for patients with AAD.

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.